Extrahepatic Malignancy Among Patients With Chronic Hepatitis C After Antiviral Therapy: A Real-World Nationwide Study on Taiwanese Chronic Hepatitis C Cohort (T-COACH)

Chung Feng Huang; Hsueh Chou Lai; Chi Yi Chen; Kuo Chih Tseng; Hsing Tao Kuo; Chao Hung Hung; Jing Houng Wang; Jyh Jou Chen; Pei Lun Lee; Rong Nan Chien; Chi Chieh Yang; Gin Ho Lo; Chi Ming Tai; Chih Wen Lin; Jia Horng Kao; Chun Jen Liu; Chen Hua Liu; Sheng Lei Yan; Ming Jong Bair; Chun Yen Lin; Wei Wen Su; Cheng Hsin Chu; Chih Jen Chen; Shui Yi Tung; Ching Chu Lo; Pin Nan Cheng; Yen Cheng Chiu; Chia Chi Wang; Jin Shiung Cheng; Wei Lun Tsai; Han Chieh Lin; Yi Hsiang Huang; Ming Lun Yeh; Jee Fu Huang; Chia Yen Dai; Wan Long Chuang; Pei Chien Tsai; Cheng Yuan Peng; Ming Lung Yu

doi:10.14309/ajg.0000000000000606

Extrahepatic Malignancy Among Patients With Chronic Hepatitis C After Antiviral Therapy: A Real-World Nationwide Study on Taiwanese Chronic Hepatitis C Cohort (T-COACH)

Chung Feng Huang, Hsueh Chou Lai, Chi Yi Chen, Kuo Chih Tseng, Hsing Tao Kuo, Chao Hung Hung, Jing Houng Wang, Jyh Jou Chen, Pei Lun Lee, Rong Nan Chien, Chi Chieh Yang, Gin Ho Lo, Chi Ming Tai, Chih Wen Lin, Jia Horng Kao, Chun Jen Liu, Chen Hua Liu, Sheng Lei Yan, Ming Jong Bair, Chun Yen LinWei Wen Su, Cheng Hsin Chu, Chih Jen Chen, Shui Yi Tung, Ching Chu Lo, Pin Nan Cheng, Yen Cheng Chiu, Chia Chi Wang, Jin Shiung Cheng, Wei Lun Tsai, Han Chieh Lin, Yi Hsiang Huang, Ming Lun Yeh, Jee Fu Huang, Chia Yen Dai, Wan Long Chuang, Pei Chien Tsai, Cheng Yuan Peng, Ming Lung Yu

內科部

研究成果: Article › 同行評審

2 引文斯高帕斯（Scopus）

摘要

INTRODUCTION: Chronic hepatitis C virus (HCV) infection is associated with nonhepatocellular carcinoma malignancies. We aimed to evaluate whether achieving a sustained virological response (SVR, defined as HCV RNA seronegativity throughout posttreatment 24-week follow-up) could reduce the risk of non-hepatocellular carcinoma malignancy in a real-world nationwide Taiwanese Chronic Hepatitis C Cohort (T-COACH). METHODS: A total of 10,714 patients with chronic hepatitis C who had received interferon-based therapy (8,186 SVR and 2,528 non-SVR) enrolled in T-COACH and were linked to the National Cancer Registry database for the development of 12 extrahepatic malignancies, including those with potential associations with HCV and with the top-ranking incidence in Taiwan, over a median follow-up period was 3.79 years (range, 0-16.44 years). RESULTS: During the 44,354 person-years of follow-up, 324 (3.02%) patients developed extrahepatic malignancies, without a difference between patients with and without SVR (annual incidence: 0.69% vs 0.87%, respectively). Compared with patients with SVR, patients without SVR had a significantly higher risk of gastric cancer (0.10% vs 0.03% per person-year, P = 0.004) and non-Hodgkin lymphoma (NHL) (0.08% vs 0.03% per person-year, respectively, P = 0.03). When considering death as a competing risk, non-SVR was independently associated with gastric cancer (hazard ratio [HR]/95% confidence intervals [CIs]: 3.29/1.37-7.93, P = 0.008). When patients were stratified by age, the effect of SVR in reducing gastric cancer (HR/CI: 0.30/0.11-0.83) and NHL (HR/CI: 0.28/0.09-0.85) was noted only in patients aged <65 years but not those aged >65 years. DISCUSSION: HCV eradication reduced the risk of gastric cancer and NHL, in particular among younger patients, indicating that patients with chronic hepatitis C should be treated as early as possible.

原文	English
頁（從 - 到）	1226-1235
頁數	10
期刊	The American journal of gastroenterology
卷	115
發行號	8
DOIs	https://doi.org/10.14309/ajg.0000000000000606
出版狀態	Published - 2020 八月 1

All Science Journal Classification (ASJC) codes

Hepatology
Gastroenterology

存取文件

10.14309/ajg.0000000000000606

指紋深入研究「Extrahepatic Malignancy Among Patients With Chronic Hepatitis C After Antiviral Therapy: A Real-World Nationwide Study on Taiwanese Chronic Hepatitis C Cohort (T-COACH)」主題。共同形成了獨特的指紋。

引用此

Huang, C. F., Lai, H. C., Chen, C. Y., Tseng, K. C., Kuo, H. T., Hung, C. H., Wang, J. H., Chen, J. J., Lee, P. L., Chien, R. N., Yang, C. C., Lo, G. H., Tai, C. M., Lin, C. W., Kao, J. H., Liu, C. J., Liu, C. H., Yan, S. L., Bair, M. J., ... Yu, M. L. (2020). Extrahepatic Malignancy Among Patients With Chronic Hepatitis C After Antiviral Therapy: A Real-World Nationwide Study on Taiwanese Chronic Hepatitis C Cohort (T-COACH). The American journal of gastroenterology, 115(8), 1226-1235. https://doi.org/10.14309/ajg.0000000000000606

Huang, Chung Feng ; Lai, Hsueh Chou ; Chen, Chi Yi ; Tseng, Kuo Chih ; Kuo, Hsing Tao ; Hung, Chao Hung ; Wang, Jing Houng ; Chen, Jyh Jou ; Lee, Pei Lun ; Chien, Rong Nan ; Yang, Chi Chieh ; Lo, Gin Ho ; Tai, Chi Ming ; Lin, Chih Wen ; Kao, Jia Horng ; Liu, Chun Jen ; Liu, Chen Hua ; Yan, Sheng Lei ; Bair, Ming Jong ; Lin, Chun Yen ; Su, Wei Wen ; Chu, Cheng Hsin ; Chen, Chih Jen ; Tung, Shui Yi ; Lo, Ching Chu ; Cheng, Pin Nan ; Chiu, Yen Cheng ; Wang, Chia Chi ; Cheng, Jin Shiung ; Tsai, Wei Lun ; Lin, Han Chieh ; Huang, Yi Hsiang ; Yeh, Ming Lun ; Huang, Jee Fu ; Dai, Chia Yen ; Chuang, Wan Long ; Tsai, Pei Chien ; Peng, Cheng Yuan ; Yu, Ming Lung. / Extrahepatic Malignancy Among Patients With Chronic Hepatitis C After Antiviral Therapy : A Real-World Nationwide Study on Taiwanese Chronic Hepatitis C Cohort (T-COACH). 於: The American journal of gastroenterology. 2020 ; 卷 115, 編號 8. 頁 1226-1235.

@article{9aeabbad08024b8687738e6544b4c65d,

title = "Extrahepatic Malignancy Among Patients With Chronic Hepatitis C After Antiviral Therapy: A Real-World Nationwide Study on Taiwanese Chronic Hepatitis C Cohort (T-COACH)",

abstract = "INTRODUCTION: Chronic hepatitis C virus (HCV) infection is associated with nonhepatocellular carcinoma malignancies. We aimed to evaluate whether achieving a sustained virological response (SVR, defined as HCV RNA seronegativity throughout posttreatment 24-week follow-up) could reduce the risk of non-hepatocellular carcinoma malignancy in a real-world nationwide Taiwanese Chronic Hepatitis C Cohort (T-COACH). METHODS: A total of 10,714 patients with chronic hepatitis C who had received interferon-based therapy (8,186 SVR and 2,528 non-SVR) enrolled in T-COACH and were linked to the National Cancer Registry database for the development of 12 extrahepatic malignancies, including those with potential associations with HCV and with the top-ranking incidence in Taiwan, over a median follow-up period was 3.79 years (range, 0-16.44 years). RESULTS: During the 44,354 person-years of follow-up, 324 (3.02%) patients developed extrahepatic malignancies, without a difference between patients with and without SVR (annual incidence: 0.69% vs 0.87%, respectively). Compared with patients with SVR, patients without SVR had a significantly higher risk of gastric cancer (0.10% vs 0.03% per person-year, P = 0.004) and non-Hodgkin lymphoma (NHL) (0.08% vs 0.03% per person-year, respectively, P = 0.03). When considering death as a competing risk, non-SVR was independently associated with gastric cancer (hazard ratio [HR]/95% confidence intervals [CIs]: 3.29/1.37-7.93, P = 0.008). When patients were stratified by age, the effect of SVR in reducing gastric cancer (HR/CI: 0.30/0.11-0.83) and NHL (HR/CI: 0.28/0.09-0.85) was noted only in patients aged <65 years but not those aged >65 years. DISCUSSION: HCV eradication reduced the risk of gastric cancer and NHL, in particular among younger patients, indicating that patients with chronic hepatitis C should be treated as early as possible.",

author = "Huang, {Chung Feng} and Lai, {Hsueh Chou} and Chen, {Chi Yi} and Tseng, {Kuo Chih} and Kuo, {Hsing Tao} and Hung, {Chao Hung} and Wang, {Jing Houng} and Chen, {Jyh Jou} and Lee, {Pei Lun} and Chien, {Rong Nan} and Yang, {Chi Chieh} and Lo, {Gin Ho} and Tai, {Chi Ming} and Lin, {Chih Wen} and Kao, {Jia Horng} and Liu, {Chun Jen} and Liu, {Chen Hua} and Yan, {Sheng Lei} and Bair, {Ming Jong} and Lin, {Chun Yen} and Su, {Wei Wen} and Chu, {Cheng Hsin} and Chen, {Chih Jen} and Tung, {Shui Yi} and Lo, {Ching Chu} and Cheng, {Pin Nan} and Chiu, {Yen Cheng} and Wang, {Chia Chi} and Cheng, {Jin Shiung} and Tsai, {Wei Lun} and Lin, {Han Chieh} and Huang, {Yi Hsiang} and Yeh, {Ming Lun} and Huang, {Jee Fu} and Dai, {Chia Yen} and Chuang, {Wan Long} and Tsai, {Pei Chien} and Peng, {Cheng Yuan} and Yu, {Ming Lung}",

note = "Copyright: This record is sourced from MEDLINE/PubMed, a database of the U.S. National Library of Medicine",

year = "2020",

month = aug,

day = "1",

doi = "10.14309/ajg.0000000000000606",

language = "English",

volume = "115",

pages = "1226--1235",

journal = "American Journal of Gastroenterology",

issn = "0002-9270",

publisher = "Nature Publishing Group",

number = "8",

}

Huang, CF, Lai, HC, Chen, CY, Tseng, KC, Kuo, HT, Hung, CH, Wang, JH, Chen, JJ, Lee, PL, Chien, RN, Yang, CC, Lo, GH, Tai, CM, Lin, CW, Kao, JH, Liu, CJ, Liu, CH, Yan, SL, Bair, MJ, Lin, CY, Su, WW, Chu, CH, Chen, CJ, Tung, SY, Lo, CC, Cheng, PN , Chiu, YC, Wang, CC, Cheng, JS, Tsai, WL, Lin, HC, Huang, YH, Yeh, ML, Huang, JF, Dai, CY, Chuang, WL, Tsai, PC, Peng, CY & Yu, ML 2020, 'Extrahepatic Malignancy Among Patients With Chronic Hepatitis C After Antiviral Therapy: A Real-World Nationwide Study on Taiwanese Chronic Hepatitis C Cohort (T-COACH)', The American journal of gastroenterology, 卷 115, 編號 8, 頁 1226-1235. https://doi.org/10.14309/ajg.0000000000000606

Extrahepatic Malignancy Among Patients With Chronic Hepatitis C After Antiviral Therapy : A Real-World Nationwide Study on Taiwanese Chronic Hepatitis C Cohort (T-COACH). / Huang, Chung Feng; Lai, Hsueh Chou; Chen, Chi Yi; Tseng, Kuo Chih; Kuo, Hsing Tao; Hung, Chao Hung; Wang, Jing Houng; Chen, Jyh Jou; Lee, Pei Lun; Chien, Rong Nan; Yang, Chi Chieh; Lo, Gin Ho; Tai, Chi Ming; Lin, Chih Wen; Kao, Jia Horng; Liu, Chun Jen; Liu, Chen Hua; Yan, Sheng Lei; Bair, Ming Jong; Lin, Chun Yen; Su, Wei Wen; Chu, Cheng Hsin; Chen, Chih Jen; Tung, Shui Yi; Lo, Ching Chu; Cheng, Pin Nan ; Chiu, Yen Cheng; Wang, Chia Chi; Cheng, Jin Shiung; Tsai, Wei Lun; Lin, Han Chieh; Huang, Yi Hsiang; Yeh, Ming Lun; Huang, Jee Fu; Dai, Chia Yen; Chuang, Wan Long; Tsai, Pei Chien; Peng, Cheng Yuan; Yu, Ming Lung.

於: The American journal of gastroenterology, 卷 115, 編號 8, 01.08.2020, p. 1226-1235.

研究成果: Article › 同行評審

TY - JOUR

T1 - Extrahepatic Malignancy Among Patients With Chronic Hepatitis C After Antiviral Therapy

T2 - A Real-World Nationwide Study on Taiwanese Chronic Hepatitis C Cohort (T-COACH)

AU - Huang, Chung Feng

AU - Lai, Hsueh Chou

AU - Chen, Chi Yi

AU - Tseng, Kuo Chih

AU - Kuo, Hsing Tao

AU - Hung, Chao Hung

AU - Wang, Jing Houng

AU - Chen, Jyh Jou

AU - Lee, Pei Lun

AU - Chien, Rong Nan

AU - Yang, Chi Chieh

AU - Lo, Gin Ho

AU - Tai, Chi Ming

AU - Lin, Chih Wen

AU - Kao, Jia Horng

AU - Liu, Chun Jen

AU - Liu, Chen Hua

AU - Yan, Sheng Lei

AU - Bair, Ming Jong

AU - Lin, Chun Yen

AU - Su, Wei Wen

AU - Chu, Cheng Hsin

AU - Chen, Chih Jen

AU - Tung, Shui Yi

AU - Lo, Ching Chu

AU - Cheng, Pin Nan

AU - Chiu, Yen Cheng

AU - Wang, Chia Chi

AU - Cheng, Jin Shiung

AU - Tsai, Wei Lun

AU - Lin, Han Chieh

AU - Huang, Yi Hsiang

AU - Yeh, Ming Lun

AU - Huang, Jee Fu

AU - Dai, Chia Yen

AU - Chuang, Wan Long

AU - Tsai, Pei Chien

AU - Peng, Cheng Yuan

AU - Yu, Ming Lung

N1 - Copyright: This record is sourced from MEDLINE/PubMed, a database of the U.S. National Library of Medicine

PY - 2020/8/1

Y1 - 2020/8/1

N2 - INTRODUCTION: Chronic hepatitis C virus (HCV) infection is associated with nonhepatocellular carcinoma malignancies. We aimed to evaluate whether achieving a sustained virological response (SVR, defined as HCV RNA seronegativity throughout posttreatment 24-week follow-up) could reduce the risk of non-hepatocellular carcinoma malignancy in a real-world nationwide Taiwanese Chronic Hepatitis C Cohort (T-COACH). METHODS: A total of 10,714 patients with chronic hepatitis C who had received interferon-based therapy (8,186 SVR and 2,528 non-SVR) enrolled in T-COACH and were linked to the National Cancer Registry database for the development of 12 extrahepatic malignancies, including those with potential associations with HCV and with the top-ranking incidence in Taiwan, over a median follow-up period was 3.79 years (range, 0-16.44 years). RESULTS: During the 44,354 person-years of follow-up, 324 (3.02%) patients developed extrahepatic malignancies, without a difference between patients with and without SVR (annual incidence: 0.69% vs 0.87%, respectively). Compared with patients with SVR, patients without SVR had a significantly higher risk of gastric cancer (0.10% vs 0.03% per person-year, P = 0.004) and non-Hodgkin lymphoma (NHL) (0.08% vs 0.03% per person-year, respectively, P = 0.03). When considering death as a competing risk, non-SVR was independently associated with gastric cancer (hazard ratio [HR]/95% confidence intervals [CIs]: 3.29/1.37-7.93, P = 0.008). When patients were stratified by age, the effect of SVR in reducing gastric cancer (HR/CI: 0.30/0.11-0.83) and NHL (HR/CI: 0.28/0.09-0.85) was noted only in patients aged <65 years but not those aged >65 years. DISCUSSION: HCV eradication reduced the risk of gastric cancer and NHL, in particular among younger patients, indicating that patients with chronic hepatitis C should be treated as early as possible.

AB - INTRODUCTION: Chronic hepatitis C virus (HCV) infection is associated with nonhepatocellular carcinoma malignancies. We aimed to evaluate whether achieving a sustained virological response (SVR, defined as HCV RNA seronegativity throughout posttreatment 24-week follow-up) could reduce the risk of non-hepatocellular carcinoma malignancy in a real-world nationwide Taiwanese Chronic Hepatitis C Cohort (T-COACH). METHODS: A total of 10,714 patients with chronic hepatitis C who had received interferon-based therapy (8,186 SVR and 2,528 non-SVR) enrolled in T-COACH and were linked to the National Cancer Registry database for the development of 12 extrahepatic malignancies, including those with potential associations with HCV and with the top-ranking incidence in Taiwan, over a median follow-up period was 3.79 years (range, 0-16.44 years). RESULTS: During the 44,354 person-years of follow-up, 324 (3.02%) patients developed extrahepatic malignancies, without a difference between patients with and without SVR (annual incidence: 0.69% vs 0.87%, respectively). Compared with patients with SVR, patients without SVR had a significantly higher risk of gastric cancer (0.10% vs 0.03% per person-year, P = 0.004) and non-Hodgkin lymphoma (NHL) (0.08% vs 0.03% per person-year, respectively, P = 0.03). When considering death as a competing risk, non-SVR was independently associated with gastric cancer (hazard ratio [HR]/95% confidence intervals [CIs]: 3.29/1.37-7.93, P = 0.008). When patients were stratified by age, the effect of SVR in reducing gastric cancer (HR/CI: 0.30/0.11-0.83) and NHL (HR/CI: 0.28/0.09-0.85) was noted only in patients aged <65 years but not those aged >65 years. DISCUSSION: HCV eradication reduced the risk of gastric cancer and NHL, in particular among younger patients, indicating that patients with chronic hepatitis C should be treated as early as possible.

UR - http://www.scopus.com/inward/record.url?scp=85089204146&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85089204146&partnerID=8YFLogxK

U2 - 10.14309/ajg.0000000000000606

DO - 10.14309/ajg.0000000000000606

M3 - Article

C2 - 32221162

AN - SCOPUS:85089204146

VL - 115

SP - 1226

EP - 1235

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 8

ER -